Announcing Launch of Nanomedical Diagnostics, Inc., a Company Releasing the World’s First Commercialized Graphene Biosensor

Share Article

New company aims to supply affordable monitoring and diagnostic platforms that empower individuals to make informed personal healthcare choices.

“We’re linking biology directly with electronics; it’s a brand new method of biomolecule monitoring that heralds a new generation of diagnostic capabilities. It’s the next step after genomics.”

Nanomed co-founders Ross Bundy and Dr. Brett Goldsmith announce the launch of Nanomedical Diagnostics, Inc., a biotech company developing and commercializing bioelectronics for use in research and diagnostics. Nanomed’s first product, AGILE Research, a label-free, quantitative, low-cost biosensor for small molecule and protein analysis, is entering beta testing this fall and planned for commercial release in early 2016.

AGILE Research is based on graphene biological field effect transistor (BioFET) technology, a field CTO Dr. Goldsmith pioneered over the past decade across both his academic and professional career. One of the few people in the world with the combined expertise in biology and nanotechnology needed to develop graphene as a viable bioelectronic device, Dr. Goldsmith teamed with his childhood friend Ross Bundy to start Nanomed at the end of 2013.

“I’ve known Ross for twenty years, attending the same high school in San Diego,” says physicist Dr. Goldsmith. “We took a physics class together and from there we completely diverged. I’ve been in nanotech while Ross worked in business. His experience in operations, business development, and finance and my work in nanotech product fabrication make us a great partnership for launching the world’s first commercialized graphene biosensor.”

After exploring a number of business ideas, the team’s vision coalesced around enabling personalized healthcare by improving diagnostic ease, speed, and cost through cutting-edge AGILE capabilities. “We have a powerful, far-reaching technology that can reshape the future of personal health,” says CEO Mr. Bundy. “We’re linking biology directly with electronics; it’s a brand new method of biomolecule monitoring that heralds a new generation of diagnostic capabilities. It’s the next step after genomics.”

Nanomed’s current focus is finalizing AGILE Research product design and will be evaluating its performance with the Centers for Disease Control and Prevention (CDC) and Stanford University. The CDC and Nanomedical Diagnostics are entering into a Cooperative Research and Development Agreement to evaluate direct electronic detection of Borrelia burgdorferi antigens for a new Lyme disease diagnostic system. Lyme disease research is also a focal point in the Stanford beta test.

Nanomed is a graduate of EvoNexus, Southern California’s leading startup technology incubator. For more information about Nanomed or AGILE Research, including pre-order opportunities, visit http://www.nanomedicaldiagnostics.com. AGILE Research is slated to launch early 2016 for research use only.

About Nanomed

Nanomedical Diagnostics Inc. (“Nanomed”) is based in San Diego, CA, and began in late 2013 with the goal of empowering individuals with the information needed to take their health into their own hands. The company’s focus is on practical products and applications that enable personalized healthcare by improving diagnostic ease, speed, and cost.

Nanomed is the first biotech company to combine expertise in biology, nanotechnology, surface chemistry, engineering, and manufacturing to create practical and scaleable graphene biological field effect transistor (BioFET) products. The company’s ongoing mission is applying cutting-edge capabilities to supply affordable monitoring and diagnostic platforms that empower individuals to make informed choices today for a healthier tomorrow.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Angela Shue
Nanomedical Diagnostics, Inc.
+1 (858) 255-4330
Email >
Visit website